Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RG 2077

Drug Profile

RG 2077

Alternative Names: CTLA4-Ig - Repligen; CTLA4-IG4m; RG1046; RG2077

Latest Information Update: 13 Apr 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Repligen
  • Class Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action CD80 antigen inhibitors; IgE receptor antagonists; Immunosuppressants; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus; Graft-versus-host disease; Idiopathic thrombocytopenic purpura; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 11 Aug 2005 No development reported - Phase-I for Graft-versus-host disease in USA (unspecified route)
  • 11 Aug 2005 No development reported - Phase-I for Idiopathic thrombocytopenic purpura in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top